Monitoring and treatment of minimal residual cancer of the prostate.
In manifest prostatic carcinoma, partial and complete remissions are obtained in 14-44% of patients as judged by different sets of criteria, but in up to 61% as judged by a decrease in prostatic acid phosphatase. Moreover, this decrease is poorly correlated to that of prostatic size. Prostatic acid phosphatase is therefore considered to be a relatively non-specific tumor marker. A complete remission, i.e. a stage of minimal residual disease, is obtained in about 25% of the patients. Continued endocrine treatment involves the risk of a flare-up of the disease, which is probably small. Additionally, in minimal residual disease, prolonged maintenance treatment requires minimization of side effects. D-Trp-6-LH-RH appears to lead to less gynecomastia and thromboembolism than some other forms of adjuvant therapy.
Mathé
G
G
Schally
A V
AV
Comaru-Schally
A M
AM
Mauvernay
R Y
RY
Vovan
M L
ML
Machover
D
D
Misset
J L
JL
Court
B
B
Bouchard
P
P
Duchier
J
J
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000628:therapy; D000469:Alkaline Phosphatase / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000032:analysis; D008297:Male; D019158:N-Acetylneuraminic Acid; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy; D012794:Sialic Acids / Q000032:analysis; D017329:Triptorelin Pamoate
D014408:Biomarkers, Tumor; D008055:Lipids; D012794:Sialic Acids; D017329:Triptorelin Pamoate; D000469:Alkaline Phosphatase; D019158:N-Acetylneuraminic Acid